Supernus Pharmaceuticals terminates UBS credit line agreement on October 20
SUPN•Supernus Pharmaceuticals terminated its UBS credit line agreement on October 20, 2026, in connection with its business combination with Indivior Pharmaceuticals. No early termination penalties were incurred.
1. Credit line termination
Supernus Pharmaceuticals terminated its UBS credit line agreement on October 20, 2026. The termination was linked to its business combination with Indivior Pharmaceuticals, and no early termination penalties were incurred.
